| 缩写名/全名 | 
                                 
                                    ALLERGY ASTHMA PROC
                                     
                            ALLERGY AND ASTHMA PROCEEDINGS  | 
                        ||||||||||||||||||||
| ISSN号 | 1088-5412 | ||||||||||||||||||||
| 研究方向 | 医学-过敏 | ||||||||||||||||||||
| 影响因子 | 2015:2.709, 2016:2.614, 2017:2.213, 2018:2.124, 2019:2.414, | ||||||||||||||||||||
| 出版国家 | UNITED STATES | ||||||||||||||||||||
| 出版周期 | Bimonthly | ||||||||||||||||||||
| 年文章数 | 82 | ||||||||||||||||||||
| 出版年份 | 1996 | ||||||||||||||||||||
| 是否OA | No | ||||||||||||||||||||
| 审稿周期(仅供参考) | 较慢,6-12周 | 
                        ||||||||||||||||||||
| 录用比例 | 较易 | ||||||||||||||||||||
| 投稿链接 | http://aap.msubmit.net/cgi-bin/main.plex | ||||||||||||||||||||
| 投稿官网 | http://www.allergyandasthmaproceedings.com/ | ||||||||||||||||||||
| h-index | 54 | ||||||||||||||||||||
| CiteScore | 
                                
  | 
                        ||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1088-5412%5BISSN%5D | ||||||||||||||||||||
| 中科院SCI期刊分区 ( 2018年新版本)  | 
                            
                                
  | 
                        ||||||||||||||||||||
| 中科院SCI期刊分区 ( 2020年新版本)  | 
                            
                                
  | 
                        
| 中国学者近期发表的论文 | |
| 1. | Real-life effectiveness of budesonide/formoterol therapy in asthma: A subanalysis of the SMARTASIA study. Author: Lin J, Tang Y, Xiu Q, Kang J, Cai S, Huang K, Itoh Y, Ling X, Zhong N. Journal: Allergy Asthma Proc. 2016 Jan-Feb;37(1):27-34. doi: 10.2500/aap.2016.37.3910. PubMed  | 
| 2. | Th1/Th2/Th17 cells imbalance in patients with asthma with and without psychological symptoms. Author: Zhu M, Liang Z, Wang T, Chen R, Wang G, Ji Y. Journal: Allergy Asthma Proc. 2016 Mar-Apr;37(2):148-56. doi: 10.2500/aap.2016.37.3928. PubMed  | 
| 3. | Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist. Author: Lin J, Tang H, Chen P, Wang H, Kim MK, Crawford J, Jacques L, Stone S. Journal: Allergy Asthma Proc. 2016 Jul;37(4):302-10. doi: 10.2500/aap.2016.37.3968. PubMed  | 
  | 
  |